ClinicalTrials.gg
CompletedNCT04466748Updated Jul 10, 2020

A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects

A Phase 1 interventional study of Anaprazole Sodium enteric-coated tablet and Placebo in Healthy Volunteers, sponsored by Sihuan Pharmaceutical Holdings Group Ltd.. Completed. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-07-10.

Sponsored by Sihuan Pharmaceutical Holdings Group Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 4 years 9 months after the study started (first participant enrolled Sep 2015, registered Jun 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

A single-center, randomized, double-blinded, placebo parallel controlled phase 1 study to evaluate the safety and pharmacokinetics/pharmacodynamics of multiple (6 days) ascending dose (20mg QD, 40mg QD, 20mg Bid) administrationof Anaprazole in healthy Chinese subjects. 36 subjects, 12 subjects for each dose group. In each dose group, 10 subjects take anaprazole, 2 subjects take placebo.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Sihuan Pharmaceutical Holdings Group Ltd. is the lead sponsor of 23 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject is capable of understanding and complying with protocol requirements, and signed and dated a written form voluntarily;
  2. The subject is a Chinese health adult, aged 18 to 45 years, inclusive;
  3. The subject weighed at least 50.0 kg and had a (BMI) between 19.0 kg/m\^2 and 24.0 kg/m\^2, inclusive;
  4. Has clinical laboratory evaluations, vital signs and testing within the reference range, and medical history and physicial examination results are normal. Participants with evaluations outside the reference range that are deemed not by the investigator may be included at investigator discretion;
  5. No medical history of allergy to proton pump inhibitors and no any other drug allergy history;
  6. The subjects have a good lifestyle and can keep good communication with the investigators and comply with the requirements of clinical trial.

Exclusion criteria

Exclusion Criteria:

  1. Has postural hypotension, gastrointestinal disease (gastric ulcer, gastritis and etc), liver disease, renal disease (nephritis, pyelonephritis and etc), and other disease or medical history of any other system (cardiovascular, respiratory, psychoneural, hematology, endocrinology and etc) ;
  2. Has clinical significant abnormal electrolytes (especially hypopotassemia) in screening examination;
  3. Has clinical significant abnormal history or family history of long syndrome(Grandparents, parents and siblings);
  4. Has rhinitis, allergic rhinitis, recurrent hemorrhinia, nasal deformity and abnormal nasal septum;
  5. With positive result of drug screening test;
  6. With positive result of nicotine test;
  7. Female participants who are pregnant, breast-feeding or menstral period, or participants has no effective method, or has pregnancy plan in 6 months;
  8. Has received any drugs: acid-inhibitors, any priscription drug, herb medicine, non-prescription drugs and/or food suppliments (including vitamine) within 2 weeks before randomization;
  9. Blood donation / blood loss ≥400 mL within 3 months, or participated any other clinical trials within 3 months;
  10. Known antibody, surface antigen, antibody, and Treponema pallidum specific antibody test results were positive at screening;
  11. Frequent alcoholics (drink more than 2 units of alcohol per day, 1 unit = 330 mL beer or 25 mL liquor or 125 mL wine), or took food or drinks with alcoholics 72 hours before randomization;
  12. Has taken foods or drinks with xanthine(cafeine) or intensive excercise. Has taken foods or drinks that affect (such as grapefruit or beverages containing grapefruit) within 14 days before administration of drugs;
  13. Smoke more than 5 pieces per week;
  14. Any conditions in which considered by investigator not be appropriate to participate in this trial.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Anaprazole Sodium enteric-coated tablet

    "Multiple ascendinng dose, anaprazole 20mg QD(20mg QD group), 40mg QD(40mg QD group), 20mg Bid(20mg Bid group) , 6 days, fasting oral administration.

    Drug: Anaprazole Sodium enteric-coated tablet

  • Placebo comparator
    Placebo

    Multiple dose, 1 tablet QD (20mg QD and 40mg QD group), 1 tablet Bid (20mg Bid group), 6 days, fasting oral administration.

    Drug: Placebo

Interventions

  • DrugAnaprazole Sodium enteric-coated tablet

    Multiple ascendinng dose, anaprazole 20mg QD(20mg QD group), 40mg QD(40mg QD group), 20mg Bid(20mg Bid group) , 6 days, fasting oral administration.

  • DrugPlacebo

    Multiple dose, 1 tablet QD (20mg QD and 40mg QD group), 1 tablet Bid (20mg Bid group), 6 days, fasting oral administration.

06

What researchers measure

Primary outcomes

  1. Number of subjects with adverse events and serious adverse events as assessed by CTCAE v5.0

    All adverse events will be monitored in each subject

    Time frame: From signing informed consent to study completion, 15 days after fist dose administration

Secondary outcomes

  1. AUC of anaprazole (parent drug, KBP-3571) and its enantiomer(KBP-3570)and its major metabolites

    AUC is area under the plasma concentration-time curve

    Time frame: 10 minutes pre-dose and 1.5、2、2.5、3、3.5、4、4.5、5、6、7、8、10、12、15、24 hours post-dose of Day 0 and Day 6

  2. Cmax of anaprazole (parent drug, KBP-3571) and its enantiomer(KBP-3570)and its major metabolites

    Cmax is the peak plasma concentration

    Time frame: 10 minutes pre-dose and 1.5、2、2.5、3、3.5、4、4.5、5、6、7、8、10、12、15、24 hours post-dose of Day 0 and Day 6

  3. Tmax of anaprazole (parent drug, KBP-3571) and its enantiomer(KBP-3570)and its major metabolites

    Tmax is the time to peak plasma concentration

    Time frame: 10 minutes pre-dose and 1.5、2、2.5、3、3.5、4、4.5、5、6、7、8、10、12、15、24 hours post-dose of Day 0 and Day 6

  4. Time percentage of gastric pH value>3 in 24 hours gastric pH monitoring post dose at day 6

    Time percentage gastric pH value\>3 is duration (hours) of gastric pH value\>3 divided to 24 hours

    Time frame: 24 hours post-dose at day 6

  5. Time percentage of gastric pH value>4 in 24 hours gastric pH monitoring post dose at day 6

    Time percentage gastric pH value\>4 is duration (hours) of gastric pH value\>3 divided to 24 hours

    Time frame: 24 hours post-dose at day 6

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2015 to primary completion in Dec 2015, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2020
First posted
Jul 10, 2020
StartActual
Sep 8, 2015
Primary completionActual
Dec 29, 2015
CompletionActual
Dec 29, 2015
Last update
Jul 10, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04466748
Responsible party
Sponsor
First posted
Jul 10, 2020
Start date
Sep 8, 2015
Primary completion
Dec 29, 2015
Completion
Dec 29, 2015
Last update
Jul 10, 2020

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion